Q32 Bio is developing therapeutics to target regulators of the innate and adaptive immune systems. Immune dysregulation is a feature and driver of several diseases. Q32 Bio is creating antibody-based therapeutics that can modulate these systems and restore homeostasis in diseased tissues. This includes their program for IL-7, a cytokine that drives pathogenic T-effector cell expansion in autoimmune diseases and their unique approach to targeting the complement system. The complement system is an integral part of the innate immune system and Q32 Bio has devised an innovative solution to complement-mediated diseases by targeting their drugs directly to the affected tissue, while allowing other important functions of the complement to remain unimpaired.

Q32 Bio

Founded: 2017
Location: Cambridge, MA
Employee range: 11 - 50
Clinical stage: Clin2
Therapy area: Atopic dermatitis
Drug types: DRM, IMM
Lead product: ADX-914 (partner: Horizon)
Funding: $60M B Oct 2020; $46M A May 2020

Drug notes:

About:

Jobs: